<DOC>
	<DOCNO>NCT01114074</DOCNO>
	<brief_summary>Rationale : Cardiovascular disease important cause morbidity mortality industrialize world . Clinical study indicate important role protein contact activation system ( coagulation factor XII ( FXII ) , FXI , prekallikrein high molecular weight kininogen ( HMWK ) ) risk cardiovascular disease . There substantial evidence mouse study FXII FXI participate formation stability thrombi vitro study show collagen able activate FXII hereby stimulate thrombin formation potentiate formation platelet-fibrin thrombus . The investigator want determine role protein contact activation system platelet mediate thrombus formation human blood . Objective : The investigator study effect protein contact activation system platelet mediate thrombus formation , embolization degradation collagen perfusion flow model . Study design : Blood collect human volunteer via venipuncture forearm . Each volunteer donate maximally four time 30 ml blood period two day . This blood use perfusion flow experiment : blood flow coverslip cover collagen flow chamber . The investigator vary several condition concentration protein shear rate . For perfusion flow experiment , investigator need fresh whole blood platelet viable four hour . After time , new blood need . Study population : For study investigator need blood human volunteer coagulation defect one proteins contact activation system , e.g . FXII , FXI , prekallikrein HMWK control without coagulation defect . Main study parameters/endpoints : The investigator main study endpoint ex vivo formation platelet-mediated thrombus collagen perfusion flow model . The investigator hypothesize thrombus form blood patient deficient FXII FXI less stable form blood control .</brief_summary>
	<brief_title>Thrombus Formation Under Different Flow-conditions</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Kininogens</mesh_term>
	<criteria>Patient group : Age : ≥ 18 year Deficiency factor XII , factor XI , prekallikrein high molecular weight kininogen Control group : Age : ≥ 18 year ( Other ) Coagulation defect Symptoms active disease The use antiplatelet drug The use aspirin/ascal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Thrombosis</keyword>
	<keyword>Blood coagulation</keyword>
	<keyword>Perfusion flow experiment</keyword>
	<keyword>Factor XII</keyword>
	<keyword>Factor XI</keyword>
	<keyword>Prekallikrein</keyword>
	<keyword>High molecular weight kininogen</keyword>
</DOC>